PALM SPRINGS, Calif., Jan. 29 - The hey day of biotech funding may have passed. But 2002 will see some big mergers, the return of the IPO, and a tighter VC environment, according to Mary Tanner, senior managing director for the pharmaceutical and biotech industries at Bear, Stearns & Co.


To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.